Increasing R&D investments for inventing different preventive methods, technological advances, and funding towards healthcare infrastructure, along with ongoing research projects, provide lucrative growth opportunities to the Global Specimen Validity Test Market
Creating a powerful tool to help confront denial and more effective drug monitoring clinical tools has improved reliance on specimen validity test (SVT)
Rising drug consumption rates across multiple age groups, increasing the need for effective drug monitoring tools, are fostering remarkable progress in global specimen validity test market.
Advantages of SVT in healthcare, such as improved therapeutic decisions in medication and illicit drug use over traditional testing tools, are encouraging the adoption of specimen validity testing. These factors are collectively influencing the growth of the global specimen validity market. These factors are likely to increase the market revenue close to USD 1.86 billion by 2028, with an annualized growth rate of 5.88% from 2021 to 2028.
A key part of the urine drug tests is specimen validity test that renders veritable data about the reliability and precision of urine drug tests, signifying that the urine psecimen submitted is valid. In addition, the specimen validity test provides scientific results evaluating the improper pill counts, abusive behaviors, clinical symptoms and assists the drug abuse, medication mismanagement, and diversion of prescribed drugs. Specimen validity tests are thus employed extensively across multiple end-user verticals.
Factors such as increasing awareness regarding the benefits of specimen validity tests, rising preferences for workplace drug testing, growing cases of drug abuse, increasing investment for alleviating drug abuse are some significant factors likely to drive the global specimen validity test market.
However, suspicion amongst screening professionals, the presence of alternative tools for drug screening, fraudulent methods causing false negatives are likely to hamper the global specimen validity test market.
Furthermore, the rising drug abuse cases across the world, accelerating foreign travel, cross migrations are increasing the need for manufacturing more specimen validity tests.
The major players in the global specimen validity test market are Thermo Fisher Scientific, CannAmm, SureHire, Clinical Reference Laboratory, ACM Global Laboratories, Alere Toxicology, Quest Diagnostics, LabCorp, Premier Biotech, Express Diagnostics, Alere, American Bio Medica Corporation, and Sciteck among all the emerging and well-established players across the world.
The market players have advanced in the science field, providing customers with more effective and innovative services and products. The products are services are provided studying customer needs. These companies have grown sporadically in revenue and customer base and have contributed majorly to the global specimen validity market.
Specimen Validity Test Market Scope
|Forecast Unit||Value (USD)|
|Revenue forecast in 2028||USD 1.86 billion|
|Growth Rate||CAGR of 5.88% during 2021-2028|
|Segment Covered||Type,Product Type, End-User, Regions|
|Regions Covered||North America, Europe, Asia Pacific, Middle East and Africa, South America|
|Key Players Profiled||Thermo Fisher Scientific, CannAmm, SureHire, Clinical Reference Laboratory, ACM Global Laboratories, Alere Toxicology, Quest Diagnostics, LabCorp, Premier Biotech, Express Diagnostics, Alere, American Bio Medica Corporation, and Sciteck among all|
Key Segments of the Global Specimen Validity Test Market
Product Type Overview, 2018-2028 (USD Billion)
- Assay Kits
- Disposable Kits
Type Overview, 2018-2028 (USD Billion)
- POC Testing
End-User Overview, 2018-2028 (USD Billion)
- Drug Rehabilitation Centers
- Pain Management
- Drug Screening
- Criminal Justice System
Regional Overview, 2018-2028 (USD Billion)
- Rest of Europe
- Rest of Asia Pacific
- Rest of South America
Middle East and South Africa
The Specimen Validity Testing Reagents is the Most Mature Segment
The global specimen validity test market is classified based on different products, namely reagents, controls, assay kits, and disposable kits. Among these segments, the specimen validity testing reagents segment has recorded maximum revenue and is projected to remain the most mature segment in the forecast span.
The key advantages such as efficient identification of adulterants and additives, ease in testing specimens, and increasing drug abuse across the world is boosting the reagents segment growth in the global specimen validity test market.
The Point of Care (POC) Segment ss the Most Lucrative Segment
The global specimen validity test market based on types is classified into laboratory and POC testing. The Point of Care Segment is expected to gather substantial market revenue. The key factors such as rapid data availability, user-friendly instruments, reduced therapeutic turnaround time is boosting the segment growth.
Workplace End User Segment to Ensure Maximum Market Revenue
The global specimen validity test market based on end-user is classified into drug rehabilitation centers, pain management, drug screening, workplace, the criminal justice system, and others. The workplace segment is anticipated to highest market revenue owing to increasing awareness of better employee health, growing need for alleviating drug abuse, reduced healthcare costs are likely to drive the segment.
North America Contributed Majorly to Market Growth
The North American countries are witnessing the increasing use of specimen validity tests owing to rising illegal drug use despite stringent law enforcement. According to studies United States has the highest rate of drug abuse and alcohol consumption. This has given to significant rise in specimen validity testing in the region.
Moreover, due to pandemic the people in the region are facing multiple mental health problems like anxiety and depression leading to increased demand for mental health services. Thus the pandemic accounted for primary testing in North America. Following APAC and Europe are also witnessing an increasing growth trend of specimen validity tests owing to misuse of opioids and stimulants, drug abuse, and many other factors.
Covid-19 Impact & Market Status
The ongoing stress and other mental health challenges, increasing drug consumption due to rising Covid-19 led concerns have led to increased demand for mental health services. According to reports, in recent months, opioid-related mortality has increased. Moreover, substance use disorders are also increasingly pushing governments to conduct specimen validity tests at workplaces, hospitals, and other places. The global specimen validity testing market is also experiencing growth due to increasing drug abuse populations and strict regulatory actions initiated to alleviate drug abuse.
This report gives a comprehensive view of the recent market developments, regulatory practices, trade scenarios, import-export, production analysis, and distribution network study of the global specimen validity test market. The report analyses the domestic, local, and players are having a global market presence.
The report identifies emerging investment avenues, potential end-user verticals, geographic landscape, and technological innovations taking place in the market. Furthermore, the report studies the market dynamics, including the market size, market share, market revenue, growth rate, and CAGR of individual market segments operating in the market.
Latest Innovations in the Global Specimen Validity Test Market: a Snapshot
- New ongoing researches are underway to develop highly efficient and cost-effective specimen validity test kits to alleviate drug abuse and improve the capabilities of existing SVTs.
- Market players, by accelerating life science research, are effortlessly working to solve complex analytical challenges in exiting tests, increasing productivity, and are delivering a combination of innovative technologies and pharmaceutical services to customers across the world.
- Global player Thermo Fisher Scientific provides complete automated specimen validity test solutions in a less expensive, efficient, and cost-effective way. The company has introduced ACT Innovation’s Paracelsus™ Software for automated specimen testing with various advanced features like randomized scheduling, participant tracking, reporting, notification, and test results.